TNF and inflammation: For these reasons, synovial inflammation and changes associated with specific OA phenotypes are considered an appropriate therapeutic target, but trials using anti-TNF [22] and anti-IL-1 have shown only weak, inconsistent results in terms of pain reduction, MRI synovitis scores, and structural progression in patients with joint inflammation associated with OA.